Val153Met polymorphism of catechol-O-methyltransferase and prevalence of uterine leiomyomata

Reproductive Sciences

Volumn 14, Issue 2, 2007, Pages 117-120

  Gooden, Kyna M ^a,e   Schroeder, Jane C ^a   North, Kari E ^a   Gammon, Marilie D ^a,b   Hartmann, Katherine E ^a,c   Taylor, Jack ^d   Baird, Donna D ^d  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e NONE   (United States)

Author keywords

Catechol O methyltransferase gene; Females; Genetic predisposition to disease; Genetics; Leiomyomata; Polymorphism; Uterine fibroids; Uterine neoplasms

Indexed keywords

CATECHOL METHYLTRANSFERASE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD EXAMINATION; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING HABIT; UTERUS CANCER; UTERUS MYOMA; AFRICAN AMERICAN; CAUCASIAN; ETHNOLOGY; GENETICS; INTERVIEW; LEIOMYOMA; MIDDLE AGED; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN AMERICANS; CATECHOL O-METHYLTRANSFERASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; INTERVIEWS; LEIOMYOMA; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; QUESTIONNAIRES; REGRESSION ANALYSIS; UTERINE NEOPLASMS;

EID: 34648831808     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719106298687     Document Type: Article

References (22)

1. Klauber N., Parangi S., Flynn E., Hamel E., D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997 ; 57: 81-86.
2. Yue TL, Wang X., Louden CS, et al. 2- Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol. 1997 ; 51: 951-962.
3. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS 2- Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 2002 ; 62: 3691-3697.
4. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A., Swartz GM, Green SJ 2- Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 2000 ; 19: 173-179.
5. Axelrod J., Tomchick R. Enzymatic O-methylation of epinephrine and catechols. J Biol Chem. 1958 ; 233: 702-705.
6. Hong CC, Thompson HJ, Jiang C., et al. Val158Met polymorphism in catechol-O-methyltransferase gene associated with risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev. 2003 ; 12: 838-847.
7. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 1999 ; 59: 4870-4875.
8. Thompson PA, Shields PG, Freudenheim JL, et al. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res. 1998 ; 58: 2107-2110.
9. Al-Hendy A., Salama SA Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig. 2006 ; 13: 136-144.
10. Baird DD, Dunson DB, Hill MC, Cousins D., Schectman JM High cumulative incidence of uterine lieomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003 ; 188: 100-107.
11. Baird DD, Dunson DB Why is parity protective for uterine fibroids? Epidemiology. 2003 ; 14: 247-250.
12. Ross P., Hall L., Smirnov I., Haff L. High-level multiplex genotyping by MALDI-TOF mass spectrometry. Nat Biotechnol. 1998 ; 16: 1347-1351.
13. Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med. 1998 ; 55: 272-277.
14. Rothman K., Greenland S. Modern Epidemiology. 2 nd ed. Philadelphia, Pa: Lippincott-Raven ; 1998.
15. Kjerulff KH, Lagenberg P., Seidman JD, Stolley PD, Guzinski GM Uterine leiomyomas: racial differences in severity, symptoms and age at diagnosis. J Reprod Med. 1996 ; 41: 483-490.
16. Marshall LM, Spiegelman D., Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997 ; 90: 967-973.
17. Faerstein E., Szklo M., Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol. 2001 ; 153: 1-10.
18. Chen C-R., Buck GM, Courey NG, Perez KM, Wactawski-Wende J. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol. 2001 ; 153: 20-26.
19. Wegienka G., Baird DD, Hertz-Picciotto I., et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol. 2003 ; 101: 431-437.
20. Herr D., Bettendorf H., Denschlag D., Keck C., Pietrowski D. Cytochrome P2A13 and P1A1 gene polymorphisms are associated with the occurrence of uterine leiomyoma. Arch Gynecol Obstet. 2006 ; 274: 367-371.
21. Al-Hendy A., Salama SA Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril. 2006 ; 86: 686-693.
22. Massart F., Becherini L., Marini F., et al. Analysis of estrogen receptor (ERalpha and ERbeta) and progesterone receptor (PR) polymorphisms in uterine leiomyomas. Med Sci Monit. 2003 ; 9: BR25 - BR30.